TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24153411
Drug: 1-week taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week taper
Study: 18290565
Drug: Basiliximab induction
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab induction therapy combined with Calcineurin inhibitors (CNI) and steroids
Study: 7739947
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg orally 1 hour before imaging procedure
Study: 2287655
Drug: Individual supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual supportive treatment plus brief counseling contacts
Study: 7255511
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (1.2 g)
Study: 30151994
Drug: PPI- AS
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI- AS group (esomeprazole 20-mg bid, rabeprazole 10-mg bid, or lansoprazole 30-mg bid; amoxicillin 750-mg bid; sitafloxacin 100-mg bid for 7 days)
Study: 7663659
Drug: rhDNase once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhDNase once daily
Study: 29987605
Drug: Breast-Conserving Therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-Conserving Therapy (BCT)
Study: 20850556
Drug: Cortisol (2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (2mg IV infusion)
Study: 20850556
Drug: Placebo (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (IV infusion)
Study: 16445306
Drug: Rivastigmine 3-12
Normalized name: rivastigmine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3-12 mg/day
Study: 10337433
Drug: Ketorolac ophthalmic
Normalized name: ketorolac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac ophthalmic solution (0.5%)
Study: 2180748
Drug: Methylprednisolone (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (low dose)
Study: 24689367
Drug: Conventional hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hormone replacement cycle without prostaglandin
Study: 21176144
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy (drotrecogin alfa at 24/30/36 μg/kg/hr for 48 to 168 hours)
Study: 21176144
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (drotrecogin alfa at 24 μg/kg/hr infusion for 96 hours)
Study: 18255347
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with stent placement
Study: 16182683
Drug: Controlled sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled sleep restriction with hypnotic administration in the first week
Study: 12634619
Drug: TLC D‐99
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC D‐99 (60 mg/m2) with cyclophosphamide (600 mg/m2)
Study: 12634619
Drug: Conventional doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doxorubicin (60 mg/m2) with cyclophosphamide (600 mg/m2)
Study: 8879472
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron, p.o.
Study: 1947853
Drug: Oral alphacalcidol
Normalized name: alfacalcidol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alphacalcidol (1 microgram daily) for 6 months
Study: 1947853
Drug: Intravenous alphacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alphacalcidol for 4 months
Study: 22908151
Drug: Omadacycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline (100 mg i.v. QD, option to transition to 200 mg orally QD)
Study: 22908151
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg i.v. BID, option to transition to 600 mg orally BID)
Study: 20004445
Drug: Restricted intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intravenous fluid regimen adjusted by serum lactate level (group A)
Study: 20004445
Drug: Restricted intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intravenous fluid regimen (group R)
Study: 16828477
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg daily for 21 days)
Study: 16828477
Drug: Estrogen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (2 mg daily for 21 days)
Study: 16828477
Drug: Estrogen+Progestagen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen+Progestagen (2 mg E(2) + 5 mg medroxyprogesterone acetate daily for 21 days)
Study: 10407221
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormonal treatment)
Study: 12492794
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with 15 ml of 0.5% bupivacaine
Study: 12492794
Drug: Psoas compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoas compartment block with 30 ml of 0.5% bupivacaine
Study: 9745421
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg
Study: 17568837
Drug: Light polymerization
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light polymerization of both the adhesive and resin cement in G-2
Study: 17568837
Drug: G-2 (opaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-2 (opaque post)
Study: 17568837
Drug: Autopolymerized adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autopolymerized adhesive in G-4
Study: 11158015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormone treatment)
Study: 10023313
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy (59.4 Gy in 6.5 weeks)
Study: 26422874
Drug: lidocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1.0 mg/kg
Study: 19924605
Drug: Low-dose pioglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone (15 mg/day)
Study: 15297687
Drug: Wheat grass
Normalized name: Wheat grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat grass juice (100 mL daily)
Study: 3540874
Drug: Amfenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amfenac 100 mg
Study: 10552992
Drug: Sequential antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antimicrobial therapy (SAT)
Study: 1757612
Drug: 0.05% halobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% halobetasol ointment
Study: 6184729
Drug: Sulprostone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulprostone (500 micrograms administered i.m. every four or six hours)
Study: 31736082
Drug: Stepped-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care treatment starting with 14 weekly sessions of manualized CBT
Study: 12045127
Drug: Control: Twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Twice-weekly rifampin plus isoniazid (not explicitly detailed in the abstract)
Study: 601870
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with isoniazid and rifampicin
Study: 601870
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with isoniazid and ethambutol
Study: 601870
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment progress
Study: 7215718
Drug: Carbenoxolone 150
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone 150 mg/day for 6 months
Study: 31585702
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation medication prescription recommended by counselor
Study: 31585702
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of inpatient smoking cessation medication
Study: 21142446
Drug: HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART treatment interruption (TI)
Study: 7581094
Drug: rhIL-6 therapy
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIL-6 therapy at 0.3 microgram/kg/day
Study: 7581094
Drug: rhIL-6 therapy
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIL-6 therapy at 1 microgram/kg/day
Study: 7581094
Drug: rhIL-6 therapy
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIL-6 therapy at 3 micrograms/kg/day
Study: 7581094
Drug: rhIL-6 therapy
Normalized name: tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIL-6 therapy (all doses)
Study: 7581094
Drug: Maximal tolerated
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tolerated dose of rhIL-6
Study: 2179979
Drug: High-dose piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose piracetam (24 g per day)
Study: 2179979
Drug: Low-dose piracetam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose piracetam (6 g per day)
Study: 30650479
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SI), 50 mL each time, once per day for 10 days
Study: 30650479
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional drugs for CHD)
Study: 21450987
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg
Study: 15358033
Drug: NCX‐4016 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX‐4016 800 mg twice a day
Study: 15358033
Drug: NCX‐4016 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX‐4016 800 mg twice a day plus aspirin 325 mg
Study: 28352985
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg qd
Study: 28352985
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg qd and Erlotinib 50 mg qd
Study: 28352985
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg qd and Erlotinib 50 mg qd (phase I MTD)
Study: 20441725
Drug: Imaginal exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal exposure therapy (3 to 5 sessions)
Study: 20441725
Drug: Imaginal exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal exposure therapy in subgroup with acute unscheduled cardiovascular events and high baseline PTSD symptoms
Study: 14649340
Drug: Non-blinded neuromuscular
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1)
Study: 14649340
Drug: Blinded neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1) (fixed rate)
Study: 11011985
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of OROS systems
Study: 11011985
Drug: Night administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night administration of OROS systems
Study: 27939406
Drug: Glutaraldehyde-modified allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaraldehyde-modified allergen extracts administered via therapeutic vaccine adsorbed onto aluminium hydroxide
Study: 26146015
Drug: Quetiapine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (25 mg)
Study: 16572265
Drug: Ondansetron (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (12 mg, oral)
Study: 8766415
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg t.i.d.)
Study: 8766415
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus Aspirin (325 mg/day)
Study: 8766415
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus Aspirin
Study: 7893494
Drug: Intermittent oxygenated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oxygenated cold Fresenius solution antegrade and retrograde (FR)
Study: 3299089
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of AZT every four hours for 24 weeks
Study: 29317123
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum high‐sensitivity C‐reactive protein (hsCRP) values <10 mg/L categorized into tertiles
Study: 8968528
Drug: Deflazacort 3
Normalized name: deflazacort 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 3 mg
Study: 8968528
Drug: Deflazacort 36
Normalized name: deflazacort 36 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 36 mg
Study: 12402720
Drug: Clonidine 4
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 4 micrograms kg‐1 infusion over 20 min, PCA clonidine 20 micrograms and morphine 1 mg bolus
Study: 12402720
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion and PCA morphine 1 mg bolus
Study: 1384117
Drug: L-carnitine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (5 g at hours 0, 12, 24, 36 and 2 x 3 g on days 3 to 7 by intravenous infusion over 2 hours)
Study: 6535339
Drug: Continue medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue medication
Study: 30665671
Drug: Control (Post-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Post-operative i.v. morphine via patient‐controlled analgesia without paravertebral blockade)
Study: 29571953
Drug: Phentolamine Mesylate
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine Mesylate (0.4 mg)
Study: 18817993
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day for initial 14 days after PCI and subsequent 30 mg/day during 6-month follow-up
Study: 10433310
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of 100 mg/kg methotrexate (MTX) over 3 hours
Study: 10433310
Drug: Regular infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular infusion of 100 mg/kg methotrexate (MTX) over 6 hours
Study: 2323312
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral naltrexone
Study: 26143022
Drug: treatment-naïve subjects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-naïve subjects
Study: 22889694
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS‐MPH)
Study: 18595749
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of intrathecal baclofen (CITB group)
Study: 18595749
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (Control group)
Study: 9014620
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg-1
Study: 3632163
Drug: Combination clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination clinical plus telephone intervention
Study: 27146116
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging program combined with nicotine patches and gum, quitline referral, and SmokefreeTXT enrollment (4 weeks duration)
Study: 24074710
Drug: Fuzhenghuayu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzhenghuayu capsule (1.5 g, 3 times/day) with continued oral NAs (one tablet, 1 time/day) for 48 weeks
Study: 15629418
Drug: Preparation for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation for Pain Management Intervention (2 sessions including assessment and feedback based on the PPMP)
Study: 15629418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual and attention placebo interview)
Study: 1993963
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo).
Study: 27590106
Drug: Topical Dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dexamethasone
Study: 18790598
Drug: Dexamphetamine 10mg
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine 10mg twice daily
Study: 12065457
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral placebo
Study: 2291877
Drug: CGP 6140
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 6140 (1200 mg single oral dose) after food intake
Study: 2291877
Drug: CGP 6140
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 6140 (1200 mg single oral dose) after an overnight fast
Study: 27301301
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 60 seconds
Study: 24854218
Drug: Intensive treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive treatment-as-usual (TAU)
Study: 19279381
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB phototherapy combined with efalizumab (1 mg/kg body weight/week)
Study: 9629935
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (suppositories or intramuscular injections of analgesics on request)
Study: 26066765
Drug: Romiplostim treatment
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim treatment
Study: 28146402
Drug: Corticosteroid at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks
Study: 28146402
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (saline injections at both time intervals)
Study: 21262998
Drug: Losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 7.5 mg twice daily for 28 days (n=27)
Study: 8833409
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n = 50)
Study: 16767907
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Study: 16767907
Drug: FLEC (5-fluoruracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLEC (5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arterially at three-weekly interval for 3 times)
Study: 10930202
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine (15 ml, 0.125%)
Study: 8105072
Drug: IVIG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (400 mg per kilogram every 28 days)
Study: 28994192
Drug: Narrow-diameter implants
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter implants (NDIs)
Study: 28994192
Drug: Regular-diameter implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-diameter implants (RDIs)
Study: 11469290
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of Depo‐Medrol (40 mg)
Study: 11469290
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of sterile saline (control)
Study: 9351634
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) high dose: 1,540 microg per day
Study: 1797602
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg simethicone
Study: 31432695
Drug: Glasdegib in
Normalized name: Product containing glasdegib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib in combination with low-dose cytarabine (LDAC)
Study: 23749683
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC)
Study: 29882961
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg microdose of dextromethorphan (DM) administered orally with CYP2D6-dependent drugs
Study: 29882961
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg microdose of dextromethorphan (DM) administered orally without CYP2D6-dependent drugs
Study: 25168125
Drug: Oral antidiabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetes agents (OADs)
Study: 18257904
Drug: Ribavirin treatment
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin treatment
Study: 20035387
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation and new drug therapies